Expired Study
This study is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active studies please search for clinical trials.

West Haven, Connecticut 06516


Purpose:

To evaluate galantamine's effects on cognitive performance in abstinent cocaine users. Galantamine, approved for treatment of Alzheimer's disease, is an acetylcholine esterase inhibitor. Galantamine also directly potentiates nicotine receptors. Both these effects may result in improved cognitive performance.


Study summary:

Galantamine, compared to placebo, will improve cognitive performance in abstinent cocaine users. The cognitive performance will be measured with the Stroop test and 3 Cambridge Neuropsychological Test Automated Battery (CANTAB) tests: Paired Associate Learning (PAL), Delayed Pattern Recognition Memory (PRM),and Rapid Visual Informatin Processing (RVIP). Performance on these tests has been shown to be impaired in abstinent cocaine users, compared to healthy controls. Galantamine, compared to placebo, will not be associated with any significant changes in mood. Monitoring of mood will be achieved with 3 mood scales: 1) Center for Epidemiologic Studies Depression (CES-D) scale, Positive and Negative Affect Schedule (PANAS) and the Profile of Mood States (POMS). Currently this study is completed, Patients are no longer being enrolled Currently 22 completers. This study has been published.


Criteria:

Inclusion Criteria: - Male and females, between the ages 21 and 50 - Fulfill criteria for past cocaine dependence - No cocaine use for the past 30 days - No other current dependence or abuse of other drugs or alcohol - No current medical problems and normal ECG - Not pregnant,nor breast feeding, - Using acceptable birth control methods. Exclusion Criteria: - Current major psychiatric illness including mood, psychotic or anxiety disorders - History of major medical illnesses; including asthma or chronic obstructive lung disease, history or current gastrointestinal ulcer, hepatic or renal impairment and cardiac rhythm disturbances - Use of other medications including,drugs that slow heart rate - Known allergy to galantamine


NCT ID:

NCT00606801


Primary Contact:

Principal Investigator
Mehmet Sofuoglu, M.D., Ph.D.
Yale University Associate Professor


Backup Contact:

N/A


Location Contact:

West Haven, Connecticut 06516
United States



There is no listed contact information for this specific location.

Site Status: N/A


Data Source: ClinicalTrials.gov

Date Processed: June 25, 2018

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.


Click to view Full Listing

This study is not currently recruiting Study Participants on ClinicalConnection.com. The form below is not enabled.